| Domain | Key facts | Quantitative evidence | Suggested ontology terms | Evidence type/key source |
|---|---|---|---|---|
| Identity | Intellectual Disability, X-linked 102 is the historical label for **DDX3X-related neurodevelopmental disorder**; synonyms include **DDX3X syndrome**, **MRX102**, and **X-linked intellectual disability–hypotonia–movement disorder syndrome**. | OMIM phenotype **300958**; MONDO **MONDO:0018709**. | MONDO:0018709; OMIM:300958 | Aggregated disease resources and foundational human genetics (pqac-00000001, pqac-00000011) |
| Causal gene | Caused by pathogenic germline variants in **DDX3X**, encoding DEAD-box helicase 3 X-linked, an ATP-dependent RNA helicase and regulator of RNA metabolism and translation. | DDX3X: Ensembl **ENSG00000215301**; foundational PMID **26235985**. | Suggested: HGNC gene **DDX3X**; GO RNA-helicase activity and RNA-metabolic-process terms | Human genetics plus biochemical/model evidence (pqac-00000001, pqac-00000008, pqac-00000011) |
| Inheritance and sex effects | Usually an X-linked disorder caused by **de novo heterozygous** variants in females. Affected males generally carry hypomorphic missense or splice-altering variants; complete loss of function is presumed poorly tolerated or embryonically lethal in hemizygous males. DDX3X escapes X-chromosome inactivation, and skewing does not reliably prevent disease. | DDX3X variants account for approximately **1–3%** of unexplained female ID. In a combined male series, **27/30** had missense and **3/30** splice-site variants; no truncating variants were reported. | HP:0001417 X-linked inheritance; suggested: abnormal X-chromosome inactivation | Human cohorts, family studies, allele-specific expression (pqac-00000001, pqac-00000003, pqac-00000010) |
| Core neurodevelopmental phenotype | Developmental delay or intellectual disability is the defining feature; language, motor, and adaptive development are commonly impaired, with severity ranging from mild to profound. | Chinese cohort: **23/23 (100%)** had ID/DD. Prospective cohort: **80%** met ID criteria. Male cohort: all had DD and/or ID; first words occurred at **18 months–8 years**. | HP:0001263 Global developmental delay; HP:0001249 Intellectual disability; HP:0000750 Delayed speech and language development; HP:0001270 Motor delay | Human prospective and retrospective cohorts (pqac-00000000, pqac-00000007, pqac-00000009) |
| Speech and communication | Expressive language is often disproportionately affected; some individuals remain minimally verbal or nonverbal. Early speech-language assessment and augmentative and alternative communication are clinically appropriate. | Published summaries estimate approximately **52%** of affected females remain nonverbal after age five; language was the most impaired developmental domain in one 23-person cohort. | HP:0001344 Severe expressive language delay; suggested: absent speech; NCIT supportive communication intervention | Human cohorts and clinical-care literature (pqac-00000007, pqac-00000013) |
| Autism, ADHD, behavior | ASD traits, ADHD, sensory-processing differences, anxiety, self-injury, stereotypies, and other behavioral difficulties occur variably. Anxiety and self-injurious behavior may be especially important clinical burdens. | Prospective cohort: ASD **60%**, ADHD **53%**. Chinese cohort: **13/17** exceeded an ASD-risk screening cutoff. Comparative study: **23** females with DDX3X variants had significantly higher anxiety and self-injury scores than 23 females with other genetic IDs. | HP:0000729 Autistic behavior; HP:0007018 Attention deficit hyperactivity disorder; HP:0100716 Self-injurious behavior; suggested: anxiety and sensory-processing abnormality | Prospective and comparative human behavioral studies (pqac-00000007, pqac-00000009) |
| Tone, movement, and motor function | Hypotonia is common but hypertonia, spasticity, ataxia, dystonic or other movement abnormalities can occur. Motor limitations affect mobility, self-care, and participation. | Chinese cohort: tone abnormalities **17/23 (73.9%)**. Male cohort: motor delay **17/18**. Earlier pooled data reported ataxia in **7/53 (13.2%)**. | HP:0001252 Hypotonia; HP:0001276 Hypertonia; HP:0001251 Ataxia; HP:0100022 Abnormality of movement | Human cohorts and case series (pqac-00000000, pqac-00000005, pqac-00000007) |
| Feeding, growth, and systemic findings | Feeding difficulty, ophthalmologic abnormalities, scoliosis or joint laxity, dysmorphism, and occasional congenital anomalies are reported. Hypothyroidism was proposed as an expanded phenotype but requires replication. | Chinese cohort: feeding difficulty **13/23 (56.5%)**, ophthalmologic problems **11/23 (47.8%)**, hypothyroidism **6/23 (26.1%)**. | HP:0011968 Feeding difficulties; HP:0000478 Abnormality of the eye; HP:0002650 Scoliosis; HP:0000821 Hypothyroidism | Human cohort; some findings are cohort-specific (pqac-00000007) |
| Epilepsy and electrophysiology | Seizures occur in a minority, with heterogeneous electroclinical presentations; abnormal EEG can occur without clinical epilepsy. | Chinese cohort: seizures **6/23 (26.1%)**, abnormal EEG **9/23 (39.1%)**. Earlier pooled series: seizures **6/53 (11.3%)**. | HP:0001250 Seizure; HP:0002353 EEG abnormality | Human cohorts (pqac-00000005, pqac-00000007) |
| Neuroimaging | MRI can be normal or show polymicrogyria, corpus-callosum dysgenesis, ventriculomegaly, delayed myelination, cerebellar/brainstem anomalies, or reduced brain volume. Recurrent severe missense variants correlate strongly with polymicrogyria and worse outcomes. | Chinese cohort: structural MRI abnormalities **15/23 (65.2%)**. Earlier pooled series: abnormal MRI **16/53 (30.2%)**, callosal abnormality **7/53 (13.2%)**. PMG prevalence across reports approximately **7–12%**. | HP:0002126 Polymicrogyria; HP:0007370 Abnormality of the corpus callosum; HP:0002119 Ventriculomegaly; HP:0012448 Delayed myelination | Human imaging cohorts and genotype–phenotype study (pqac-00000001, pqac-00000002, pqac-00000005, pqac-00000007) |
| Pathogenic variants | Disease-associated variants include nonsense, frameshift, canonical and noncanonical splice, missense, in-frame deletion, insertion, and duplication alleles. Female truncating variants usually support haploinsufficiency; severe helicase-domain missense variants may exert dominant-negative or toxic effects through impaired RNA release and granule formation. Population allele frequencies are variant-specific and must be checked in current gnomAD/ClinVar records. | Largest mechanistic cohort included **107** affected individuals; a Chinese cohort found **22** deleterious de novo variants among **2,317** probands. | SO terms suggested by variant: missense_variant, frameshift_variant, stop_gained, splice_region_variant; ACMG P/LP/VUS | Human molecular cohorts plus functional assays (pqac-00000001, pqac-00000003, pqac-00000004, pqac-00000007) |
| Mechanism | DDX3X dysfunction impairs ATP-dependent RNA unwinding, translation of structured transcripts, and RNA-protein-granule dynamics. This disrupts neural-progenitor cell-cycle timing, neurogenic divisions, neuron production and migration, producing abnormal cortical lamination or PMG and downstream cognitive, language, motor, and behavioral impairment. Wnt effects are established in earlier experiments; newer model evidence links DDX3X loss to impaired **CREBBP-mRNA stabilization and Notch signaling**. | Severe missense variants show the strongest human association with PMG and severe outcomes; quantitative molecular effects vary by allele/model. | GO:0006396 RNA processing; GO:0006412 translation; GO:0007049 cell cycle; GO:0022008 neurogenesis; GO:0001764 neuron migration; suggested Wnt- and Notch-signaling GO terms | Human genotype–phenotype correlation; mouse, cell, biochemical, ribosome-profiling, zebrafish and Xenopus evidence (pqac-00000001, pqac-00000002, pqac-00000008, pqac-00000009) |
| Cells, tissues, and compartments | The primary affected organ is the developing CNS, especially fetal cerebral cortex. Implicated cells include radial glia/neural stem and progenitor cells, migrating neurons, and cortical excitatory neurons. Relevant compartments include cytoplasmic ribonucleoprotein granules, ribosomes, nucleus, and cytoplasm. | Mouse haploinsufficiency produces reduced brain volume and abnormal cortical lamination; conditional loss reduces neurogenesis. | UBERON:0000955 brain; suggested cerebral cortex; CL:0000047 neuronal stem cell; CL:0000540 neuron; GO:0035770 ribonucleoprotein granule; suggested ribosome/nucleus/cytoplasm terms | Mouse and cellular models; anatomical inference from human MRI (pqac-00000001, pqac-00000006, pqac-00000009) |
| Diagnosis | Diagnosis requires a compatible neurodevelopmental phenotype plus a pathogenic/likely pathogenic germline DDX3X variant. Trio exome/genome sequencing is preferred for unexplained ID/DD because it establishes de novo status and detects broad differential diagnoses. A neurodevelopmental panel including DDX3X or single-gene sequencing with deletion/duplication analysis is also usable. CMA detects CNVs but usually misses single-nucleotide variants; karyotype, FISH, mtDNA and repeat-expansion testing are not targeted tests for this disorder. | No disease-specific biochemical biomarker. WES identified **22 female de novo variants** in a 2,317-proband cohort; male diagnoses may require cautious interpretation and functional evidence. | NCIT suggested: Genetic Testing, Whole Exome Sequencing, Whole Genome Sequencing, Chromosomal Microarray; HP phenotype terms for variant prioritization | Clinical sequencing cohorts and expert interpretation (pqac-00000000, pqac-00000003, pqac-00000007) |
| Clinical evaluation | Baseline evaluation should be multidisciplinary: developmental/cognitive and adaptive assessment; speech-language and AAC evaluation; neurologic examination; ASD/ADHD/anxiety and sensory assessment; feeding/growth, vision and hearing assessment; musculoskeletal review; EEG if seizure concern; MRI when neurologic signs, seizures, abnormal head growth, or significant motor findings warrant it. | NCT03718910 used a three-day neurologic, psychiatric, developmental, medical, EEG, visual-evoked-potential and eye-tracking battery in **15** participants. | NCIT suggested: Neurologic Examination, Developmental Assessment, Magnetic Resonance Imaging, Electroencephalography, Ophthalmologic Examination | Expert-care recommendations and observational implementation; individual schedules remain phenotype-driven (pqac-00000008, pqac-00000012) |
| Management | No approved disease-modifying therapy exists. Care is symptomatic and supportive: early developmental intervention; speech-language/AAC, occupational and physical therapy; behavioral and educational supports; feeding therapy/nutrition; standard antiseizure treatment; management of tone, movement, sleep, anxiety/ADHD, scoliosis, vision, hearing, and endocrine problems as clinically indicated. | No disorder-specific response-rate or comparative-treatment data. Case-level therapy reports cannot establish efficacy. | NCIT suggested: Supportive Care, Physical Therapy, Occupational Therapy, Speech Therapy, Behavioral Therapy, Anticonvulsant Therapy, Nutritional Support | Expert opinion and case-level implementation (pqac-00000008, pqac-00000013) |
| Research and trials | Clinical research is currently centered on natural history, deep phenotyping, biomarkers and patient registries rather than interventional molecular therapy. | **NCT03718910**: completed observational study, **15** participants, May 23, 2018–June 1, 2020. **NCT01238250 (Simons Searchlight)**: recruiting umbrella observational registry, planned enrollment **100,000** across eligible genetic conditions. | NCIT suggested: Observational Study, Natural History Study, Patient Registry | ClinicalTrials.gov registry evidence (pqac-00000012) |
| Prognosis and course | Onset is congenital/early childhood and the neurodevelopmental disability is generally lifelong. Severity and independence vary widely. Limited reports describe later motor decline in some individuals or males with hypomorphic alleles, but progression is not established as the typical course. | No disease-specific life-expectancy, survival, mortality, remission, or validated prognostic-biomarker estimates are available. | HP:0003593 Infantile onset or suggested early-childhood onset; suggested chronic course | Human cohorts and rare longitudinal observations; major evidence gaps remain (pqac-00000000, pqac-00000001) |
| Epidemiology | Ultra-rare Mendelian disorder found across ancestries; ascertainment is strongly female-biased because most recognized cases are de novo heterozygous females. No founder effect, endemic region, or reliable population prevalence/incidence has been established. | Approximately **1–3% of unexplained female ID**, not 1–3% of all females. Disease-specific carrier frequency is unavailable. | MONDO:0018709; HP:0001417 | Sequencing-cohort estimate, not population epidemiology (pqac-00000001, pqac-00000007) |
| Risk, protection, and environment | The causal risk is a pathogenic germline DDX3X variant. Variant class/location, residual activity, sex, DDX3Y compensation in males, and possibly X-inactivation modify expression. No validated environmental causal, protective, infectious, toxin, lifestyle, dietary, occupational, immune, or gene–environment factor is known. | No quantified environmental effect sizes or protective alleles reported. | Suggested: genetic modifier; X-chromosome inactivation; not applicable for infectious-agent ontology | Human genetics and model-based modifier evidence; explicit knowledge gap (pqac-00000003, pqac-00000009, pqac-00000010) |
| Prevention and counseling | The phenotype cannot be prevented after a causal de novo variant arises. Primary prevention consists of reproductive counseling and optional prenatal or preimplantation testing after the familial variant is known. Cascade testing is appropriate for inherited male-family alleles; parental testing also assesses recurrence risk, although low residual risk from germline mosaicism remains after an apparently de novo result. Tertiary prevention is early therapy and complication surveillance. | Exact germline-mosaicism and recurrence rates are unavailable; no newborn population screening or prophylactic medication is established. | NCIT suggested: Genetic Counseling, Prenatal Genetic Testing, Preimplantation Genetic Testing, Cascade Testing, Early Intervention | Standard Mendelian-genetics practice informed by de novo/inherited cohorts (pqac-00000000, pqac-00000003, pqac-00000004) |
| Models and comparative biology | Available experimental systems include Ddx3x haploinsufficient and neural conditional-knockout mice, zebrafish functional assays, Xenopus neural-crest models, and cultured neural progenitor/neuronal systems. Models reproduce neurogenesis, cortical-lamination, motor, behavioral, and brain-volume abnormalities but cannot capture the full human language and adaptive phenotype. No naturally occurring veterinary equivalent or zoonotic transmission is established. | Ddx3x+/− mice show developmental, sensory and motor delays, adult hyperactivity/anxiety-like behavior, cognitive/motor deficits and reduced brain volume. | NCBI Taxon suggested: Homo sapiens, Mus musculus, Danio rerio, Xenopus tropicalis; NCIT suggested: Animal Model, Cell Culture Model | Mouse, zebrafish, Xenopus and in-vitro evidence (pqac-00000006, pqac-00000009) |
| Explicit unavailable items | No validated metabolomic, lipidomic, circulating-protein, epigenomic or liquid-biopsy diagnostic signature; no established modifier gene, protective variant, pharmacogenomic rule, surgical treatment, gene/cell/RNA therapy, immunotherapy, or disease-specific prevention program. Somatic DDX3X cancer variants must not be conflated with germline DDX3X syndrome. | No approved targeted drug and no interventional DDX3X-syndrome trial identified in the searched evidence. | Ontology mapping not applicable until evidence exists | Negative database/registry finding and evidence-gap assessment (pqac-00000011, pqac-00000012) |


*Table: Concise knowledge-base table integrating identifiers, genetics, phenotypes, mechanisms, diagnosis, management, research studies, ontology suggestions, and explicit evidence gaps for Intellectual Disability X-linked 102.*